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ABSTRACT 
Recent in vitro and in vivo studies have demonstrated that zerumbone (ZER) possesses 
anticancer properties. The main objective of this study was to examine the effectiveness of 
the combination of ZER and cisplatin (CIS) to treat cervical intraepithelial neoplasia (CIN) in 
vivo. Microculture tetrazolium assay and immunohistochemistry of proliferating cellular 
nuclear antigen were used to study the antitumor effect of ZER.Prenatally exposed female 
BALB/c micewere used as a model. The progenies with CIN were injected peritoneally with 
isotonic sodium chloride solution (positive control), CIS, ZER,and a combination of both 
compounds. All treated and untreated mice were humanely killed, and serum and cervix were 
obtained for interleukin 6 analysis and histopathologic studies using hematoxylin and eosin 
staining, respectively. Zerumbone has revealed an antitumor effect on human cervical cancer 
cells and downregulates immunoexpression of proliferating cellular nuclear antigen (P < 
0.05). In vivo study indicates that ZER at 16 mg/kg and CIS at 10 mg/kg have a regressing 
effect on CIN. The combination of ZER and CIS also showed similar effectiveness in 
regressing CIN. Our results indicate that the combination of ZER and CIS has modulated the 
serum level of interleukin 6 when compared with that in mice treated with isotonic sodium 
chloride solution (P < 0.05). The effectiveness of combining ZER and CIS could be further 
explored as a new therapeutic intervention of early precancerous stages of carcinogenesis 
before the invasive stage begins. 
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